Prurigo nodularis
diseaseOn this page
Summary
Prurigo nodularis (MONDO:0026045) is a disease with 3 GWAS associations across 3 studies and 44 clinical trials. Top therapeutic interventions include nemolizumab, abrocitinib, and apremilast. A subtype of skin disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 3
- Clinical trials: 44
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | prurigo nodularis |
| Mondo ID | MONDO:0026045 |
| ICD-10-CM | L28.1 |
| UMLS | C0263353 |
| MedGen | 120471 |
| Is cancer (heuristic) | no |
Data availability: 3 GWAS associations (3 studies).
Disease family
This is a subtype of skin disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › prurigo nodularis
Related subtypes (71): dermatitis, cutaneous mucinosis, skin neoplasm, pyoderma, chronic ulcer of skin, systemic sclerosis, sunburn, severe cutaneous adverse reaction, paronychia, Achenbach syndrome, erythema multiforme, erythematosquamous dermatosis, exanthem, facial dermatosis, hand dermatosis, keratosis, leg dermatosis, lichen disease, lipodystrophy, mongolian spot, reactive cutaneous fibrous lesion, rosacea, scalp dermatosis, sebaceous gland disorder, skin atrophy, skin sarcoidosis, sweat gland disorder, vesiculobullous skin disease, hyperglobulinemic purpura, ainhum, cheilitis glandularis, erythema palmare hereditarium, multiple benign circumferential skin creases on limbs, actinic prurigo, congenital lethal erythroderma, Parana hard-skin syndrome, Bazex-Dupre-Christol syndrome, nephrogenic systemic fibrosis, erosive pustular dermatosis of the scalp, pseudoxanthoma elasticum-like papillary dermal elastolysis, toxic dermatosis, oral erosive lichen, chronic actinic dermatitis, Jessner lymphocytic infiltration of the skin, acquired kinky hair syndrome, primary cutaneous plasmacytosis, cutaneous pseudolymphoma, corticosteroid-sensitive aseptic abscess syndrome, interstitial granulomatous dermatitis with arthritis, epidermal disease, skin pigmentation disorder, skin vascular disease, Wells syndrome, solar urticaria, pellagra, hereditary epidermal appendage anomaly, keratosis pilaris, dermis disorder, aquagenic pruritus, Boudhina Yedes Khiari syndrome, non-neoplastic nevus, cutaneous sclerosis, pityriasis rotunda, hematohidrosis, skin disorder caused by infection, livedoid vasculopathy, granuloma faciale, sclerema neonatorum, hereditary skin disorder, hand-foot syndrome, Nicolau syndrome
Genetics & variants
GWAS landscape
3 GWAS associations across 3 studies. Top hits map to 2 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs6039266 | 5e-08 | PLCB1 | ? | 3.15 |
| rs34217906 | 6e-07 | TXNRD1 | ? | 1.71 |
| rs7134193 | 1e-06 | TXNRD1 | ? | 1.57 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90297846 | Vasavda C | 2023 | 480 | 235,068 | A polygenic risk score for predicting racial and genetic susceptibility to prurigo nodularis. |
| GCST90297844 | Vasavda C | 2023 | 309 | 198,740 | A polygenic risk score for predicting racial and genetic susceptibility to prurigo nodularis. |
| GCST90297845 | Vasavda C | 2023 | 171 | 36,328 | A polygenic risk score for predicting racial and genetic susceptibility to prurigo nodularis. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 1 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 2 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 2 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 2 |
| missense_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs6039266 | 20 | 8785424 | A>G,T | 0.045 | intron_variant | PLCB1 | 5e-08 | Tier 4: intronic/intergenic |
| rs34217906 | 12 | 104261940 | T>G | 0.018 | intron_variant | TXNRD1 | 6e-07 | Tier 4: intronic/intergenic |
| rs7134193 | 12 | 104310058 | A>C,G | 0.05 | missense_variant | TXNRD1 | 1e-06 | Tier 1: coding |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 44.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 14 |
| PHASE2 | 10 |
| Not specified | 10 |
| PHASE2/PHASE3 | 4 |
| PHASE1 | 3 |
| PHASE4 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03630198 | PHASE4 | COMPLETED | Pain Outcomes Following Intralesional Corticosteroid Injections |
| NCT06773403 | PHASE4 | TERMINATED | Upadacitinib for Prurigo Nodularis |
| NCT04204616 | PHASE3 | ACTIVE_NOT_RECRUITING | A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) |
| NCT06293053 | PHASE3 | RECRUITING | A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis |
| NCT06424470 | PHASE3 | ACTIVE_NOT_RECRUITING | Study on the Treatment of Prurigo Nodularis With Stapokibart Injection |
| NCT06516952 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) |
| NCT06516965 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) |
| NCT06527404 | PHASE3 | ACTIVE_NOT_RECRUITING | A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis |
| NCT06554509 | PHASE2/PHASE3 | RECRUITING | Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis |
| NCT06779136 | PHASE3 | RECRUITING | Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis |
| NCT02174419 | PHASE2/PHASE3 | COMPLETED | Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis |
| NCT02174432 | PHASE2/PHASE3 | COMPLETED | Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis |
| NCT03497975 | PHASE2/PHASE3 | COMPLETED | PRISM Study-Pruritus Relief Through Itch Scratch Modulation |
| NCT03540160 | PHASE3 | TERMINATED | Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) |
| NCT03546816 | PHASE3 | COMPLETED | Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis |
| NCT03677401 | PHASE3 | COMPLETED | Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis |
| NCT04501666 | PHASE3 | COMPLETED | Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) |
| NCT04501679 | PHASE3 | COMPLETED | A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) |
| NCT05052983 | PHASE3 | COMPLETED | A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis |
| NCT05764161 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) |
| NCT06366750 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Barzolvolimab in Patients With Prurigo Nodularis |
| NCT06994520 | PHASE2 | ACTIVE_NOT_RECRUITING | Efficacy of Topical Cannabidiol for Eczema |
| NCT07236099 | PHASE2 | RECRUITING | Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis |
| NCT00507832 | PHASE2 | COMPLETED | Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease |
| NCT00869089 | PHASE2 | COMPLETED | Safety and Efficacy of CC-10004 for Prurigo Nodularis |
| NCT02196324 | PHASE2 | COMPLETED | A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) |
| NCT03181503 | PHASE2 | COMPLETED | Safety and Efficacy of Nemolizumab in PN |
| NCT03576287 | PHASE1/PHASE2 | UNKNOWN | Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis |
| NCT03816891 | PHASE2 | COMPLETED | Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis |
| NCT05038982 | PHASE2 | COMPLETED | Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin |
| NCT05061693 | PHASE2 | COMPLETED | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis |
| NCT06342713 | PHASE1 | RECRUITING | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases |
| NCT04944862 | PHASE1 | COMPLETED | A Study of CDX-0159 in Patients With Prurigo Nodularis |
| NCT06213831 | PHASE1 | COMPLETED | A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream |
| NCT05316805 | Not specified | RECRUITING | China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project |
| NCT05928169 | Not specified | RECRUITING | Determinants of Chronic Inflammatory Skin Disease Trajectories |
| NCT05991323 | Not specified | ACTIVE_NOT_RECRUITING | Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study |
| NCT06087627 | Not specified | RECRUITING | A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine |
| NCT06988618 | Not specified | RECRUITING | Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults |
| NCT07276425 | Not specified | RECRUITING | Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| NEMOLIZUMAB | 4 | 5 |
| ABROCITINIB | 4 | 1 |
| APREMILAST | 4 | 1 |
| DUPILUMAB | 4 | 1 |
| NALBUPHINE | 4 | 1 |
| PIMECROLIMUS | 4 | 1 |
| RUXOLITINIB | 4 | 1 |
| UPADACITINIB | 4 | 1 |
| SERLOPITANT | 3 | 4 |
| POVORCITINIB | 3 | 3 |
| BARZOLVOLIMAB | 3 | 2 |
| ROCATINLIMAB | 3 | 1 |
| STAPOKIBART | 3 | 1 |
| VIXARELIMAB | 2 | 1 |
| CHEMBL4783966 | 0 | 1 |
| CHEMBL4637163 | 0 | 1 |
| CHEMBL475165 | 0 | 1 |